Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its underwritten public offering of 5 million shares of common stock at $20.00 per share, with expected gross proceeds of approximately $100 million, the company announced. The offering includes a 30-day option for underwriters to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary conditions.
The company plans to use the net proceeds to advance development of its NXP100, NXP200, and NXP900 programs, support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes. Cantor is serving as sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners acting as co-managers.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focusing on innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100, a complement Factor B inhibitor with best-in-class potential for complement-mediated diseases; NXP200, a brain-penetrant paradox-breaker BRAF inhibitor for various solid tumors; and NXP900, an oral small molecule inhibitor targeting SRC family kinases. The funding is crucial for advancing these programs, particularly NXP100, which the company believes could offer a once-daily oral treatment advantage for diseases requiring lifelong therapy.
The offering represents a significant capital injection for the company, enabling it to push its drug candidates through clinical development. For investors, this move signals confidence in Nuvectis's pipeline and its potential to address unmet medical needs in both complement-mediated diseases and oncology.
For more information, visit https://nuvectis.com/.
